Petros Grivas, MD
Immunotherapy is likely to represent the future of bladder cancer care, especially in combinations with chemotherapy and targeted therapy regimens, according to Petros Grivas, MD.
, Grivas shared insight on the value of combining immunotherapy regimens in the treatment of patients with urothelial carcinoma.
OncLive: Please provide an overview of your presentation on bladder cancer.
: I discussed the recent updates with immunotherapy, specifically immune checkpoint inhibitors, in the management of patients with advanced urothelial carcinoma. Over the last couple of years, we have seen data with 5 FDA approvals of immune checkpoint inhibitors for the management of patients with platinum-refractory advanced urothelial cancer.
... to read the full story